TDM-optimized Teicoplanin Dosing Versus Standard of Care

• Status: Recruiting
• Trial end date: 2024-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Value of TDM for teicoplanin is not well defined. In this single-center low-interventional randomized trial the investigators aim to investigate the superiority of teicoplanin TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus the standard of care (dosing based on antibiotic guidelines) in target attainment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University Medical Center
• Collaborator: ZonMw: The Netherlands Organisation for Health Research and Development
• Treatments: Teicoplanin

Criteria

Inclusion Criteria:

1. The patient is admitted to the ICU, haematology, gastroenterology or orthopaedics department.

2. The patient is at least 18 years old on the day of inclusion.

3. The patient is treated with teicoplanin as part of standard care.

4. The patient or a representative is willing to sign the Informed Consent Form

Exclusion Criteria:

1. The patient has previously participated in this study.

2. The patient receives any form of renal replacement criteria (RRT) other than CVVHD / CVVHDF.

3. Expected duration of teicoplanin therapy is less than 5 days.

4. The patient is pregnant